Perrigo Q2 Net Sales Up 7.3% to $1.17B, Swings to Profit

TL;DR

**Perrigo's Q2 comeback is real, buy the dip if you missed it, they're executing.**

AI Summary

Perrigo Co plc reported a robust financial performance for the second quarter ended June 28, 2025, with net sales reaching $1.17 billion, marking a 7.3% increase from $1.09 billion in the prior-year quarter. The company's net income significantly improved, swinging from a net loss of $15.5 million in Q2 2024 to a net income of $45.2 million in Q2 2025. This positive shift was primarily driven by strong demand in its Consumer Self-Care Americas (CSCA) segment, which saw sales grow by 9.1% to $780 million. The Consumer Self-Care International (CSCI) segment also contributed positively, with sales increasing by 4.5% to $390 million. Key business changes include continued focus on its self-care portfolio and strategic divestitures of non-core assets. Risks highlighted include ongoing supply chain volatility and inflationary pressures impacting raw material costs, though the company has largely mitigated these through pricing strategies. The strategic outlook emphasizes sustained growth in its core self-care categories and disciplined capital allocation.

Why It Matters

Perrigo's strong Q2 2025 performance, particularly the swing to a $45.2 million net income, signals effective management and a resilient business model in the competitive consumer healthcare market. For investors, this indicates a potential for sustained profitability and a more attractive valuation compared to competitors like Johnson & Johnson or Procter & Gamble, which also operate in consumer health. Employees benefit from a stable and growing company, while customers gain from continued product availability and innovation in self-care. The broader market sees a key player in over-the-counter healthcare demonstrating strength amidst economic headwinds, potentially influencing sector sentiment positively.

Risk Assessment

Risk Level: medium — While Perrigo reported strong growth, the company still faces 'ongoing supply chain volatility' and 'inflationary pressures' as noted in the filing, which could impact future profitability. Additionally, the company's long-term debt remains substantial, with various senior notes outstanding, including $4.900 Senior Notes Due June 15, 2030, and $6.125 Senior Notes Due 2032, which could pose refinancing risks in a rising interest rate environment.

Analyst Insight

Investors should consider increasing their position in PRGO, given the significant improvement in net income and robust sales growth in both key segments. Monitor the company's ability to manage ongoing supply chain and inflationary pressures, as sustained mitigation will be crucial for long-term performance.

Financial Highlights

revenue

$1.17B

net Income

$45.2M

revenue Growth

+7.3%

Revenue Breakdown

Key Numbers

• $1.17B — Net Sales for Q2 2025 (Increased by 7.3% from $1.09 billion in Q2 2024)
• $45.2M — Net Income for Q2 2025 (Swing from a net loss of $15.5 million in Q2 2024)
• 7.3% — Year-over-year Net Sales Growth (Reflects strong demand across segments)
• $780M — CSCA Net Sales for Q2 2025 (Increased by 9.1% from prior year)
• $390M — CSCI Net Sales for Q2 2025 (Increased by 4.5% from prior year)

Key Players & Entities

• PERRIGO Co plc (company) — filer of the 10-Q
• Consumer Self-Care Americas (company) — segment of Perrigo
• Consumer Self-Care International (company) — segment of Perrigo
• Johnson & Johnson (company) — competitor in consumer healthcare
• Procter & Gamble (company) — competitor in consumer healthcare

FAQ

Risk Factors

• Supply Chain Volatility [medium — operational]: The company faces ongoing supply chain disruptions which can impact the availability and cost of raw materials. While largely mitigated through pricing strategies, continued volatility poses a risk to consistent production and delivery.
• Inflationary Pressures [medium — financial]: Rising costs for raw materials due to inflation present a challenge. Perrigo has implemented pricing strategies to offset these increases, but sustained inflationary trends could erode margins if not fully passed on to consumers.

Industry Context

Perrigo operates in the pharmaceutical preparations and consumer healthcare sectors, a competitive landscape characterized by brand loyalty, regulatory oversight, and increasing consumer demand for self-care solutions. Key trends include a shift towards over-the-counter (OTC) medications and a growing emphasis on private label and generic alternatives.

Regulatory Implications

As a pharmaceutical and consumer healthcare company, Perrigo is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, product safety, and marketing claims is critical. Changes in regulatory policies or increased enforcement could impact product approvals and market access.

What Investors Should Do

1. Monitor margin performance
2. Assess CSCA growth drivers
3. Evaluate strategic divestitures

Key Dates

• 2025-06-28: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing net sales of $1.17 billion and net income of $45.2 million.
• 2024-06-29: End of Second Quarter 2024 — Prior year comparison period, which reported a net loss of $15.5 million.

Glossary

Consumer Self-Care Americas (CSCA)

Perrigo's business segment focused on consumer healthcare products sold in North America. (This segment is a key driver of revenue growth, with a 9.1% increase in Q2 2025.)

Consumer Self-Care International (CSCI)

Perrigo's business segment focused on consumer healthcare products sold outside of North America. (This segment also contributed to overall growth, with a 4.5% increase in Q2 2025.)

Year-Over-Year Comparison

Perrigo has demonstrated significant improvement in its financial performance compared to the prior year's filing. Net sales increased by 7.3% to $1.17 billion in Q2 2025, a substantial turnaround from the net loss of $15.5 million reported in Q2 2024, swinging to a net income of $45.2 million. This positive trend is supported by robust growth in both the CSCA and CSCI segments, indicating effective demand across its self-care portfolio.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding PERRIGO Co plc (PRGO).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR